A Better Newspaper

## Overview On April 18, 2026, President Trump signed an executive order directing the federal government to relax restrictions on psychedelic substances, including ibogaine, for potential therapeutic and medical treatment purposes (Al Jazeera, April 18). Podcast host Joe Rogan was present at the signing, signaling an unusual intersection of media influence and regulatory policymaking. ## Scope of the Order The order reportedly calls on the federal government to accelerate review timelines and ease regulatory barriers for psychedelic-assisted treatments (Al Jazeera, April 18). Ibogaine — a plant-derived psychoactive compound with reported efficacy in treating opioid addiction and PTSD — was specifically mentioned. The order does not appear to constitute full rescheduling of controlled substances, but rather mandates a review process. ## Ibogaine Ibogaine is currently a Schedule I controlled substance in the United States. It has been the subject of growing clinical interest, particularly for opioid use disorder and treatment-resistant depression. Several countries, including Mexico and Canada, permit or tolerate ibogaine clinics. The executive order may accelerate FDA breakthrough therapy designations or DEA scheduling reviews. ## Joe Rogan's Role Rogan's presence at the signing (Al Jazeera, April 18) is notable given his longstanding advocacy for psychedelic research on his widely-followed podcast. His involvement suggests the administration is cultivating non-traditional media relationships to build public support for the policy shift. ## Legal & Regulatory Implications - **DEA scheduling**: Any rescheduling of ibogaine or other psychedelics requires notice-and-comment rulemaking under the Controlled Substances Act; executive direction can accelerate but not bypass this process. - **FDA pathway**: Breakthrough Therapy designation or accelerated approval pathways could be directed administratively. - **Investment**: Publicly-traded psychedelic therapy companies (e.g., MAPS, Cybin, MindMed) may see significant valuation impacts as regulatory risk profile shifts. - **State law interaction**: Several states (Oregon, Colorado) have already legalized psilocybin; federal relaxation could harmonize or complicate the patchwork regulatory landscape. ## Broader Context The order represents a continuation of Trump administration deregulatory health policy, potentially affecting veterans' mental health treatment programs where psychedelic therapies have shown clinical promise. Congressional action may be required for full rescheduling, making the legislative track a developing story. ## Key Figures - **Donald Trump**: Signed the order (Al Jazeera, April 18). - **Joe Rogan**: Present at signing; advocate for psychedelic research (Al Jazeera, April 18).